Paratek Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

Paratek Pharmaceuticals

10/05/2023 01:12

* Paratek Pharmaceuticals Inc  PRTK.OQ  reported a quarterly
adjusted loss of 35 cents​​ per share for the quarter ended in
March. The mean expectation of three analysts for the quarter
was for a loss of 42 cents per share.
    * Revenue rose 25.6% to $31.24 million from a year ago;
analysts
expected $30.08 million. 
    * Paratek Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 35 cents​.
    * The mean earnings estimate of analysts had fallen by
about 1,500% in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate 
    * Paratek Pharmaceuticals Inc shares had fallen by 29.1%
this
quarter and lost 3.7% so far this year.
    * The company reported a quarterly loss of $20.14 million.
    * Wall Street's median 12-month price target for Paratek
Pharmaceuticals Inc is $5.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 3 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
10 at 12:12 a.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.42          -0.35          Beat
 Dec. 31 2022      0.09           -0.12          Missed
 Sep. 30 2022      -0.29          -0.38          Missed
 Jun. 30 2022      -0.34          -0.33          Beat